ClinicalTrials.Veeva

Menu

Pilot Study Utilising an Impression Technique to Capture in Vivo Images of Teeth

Unilever logo

Unilever

Status

Completed

Conditions

Tooth Erosion

Treatments

Other: Water
Other: RS01

Study type

Interventional

Funder types

Other
Industry

Identifiers

NCT02676219
ORL-IST-2190

Details and patient eligibility

About

The study design is a randomised, split mouth, blind with respect to study analysts (microscopist, image grader) two treatment clinical study in 10 healthy participants with sound tooth enamel. The study will comprise of a screening visit, pre-baseline visit and 5 subsequent clinic visits. At the screening visit, participants will give consent to participate in the study. Medical history and concomitant medications will be recorded. Eligibility will be determined following an oral soft tissue (OST) examination and an evaluation of dentition exclusions. Two suitable anterior teeth will be identified for study assessments, these teeth must be at least one tooth apart in the mouth. Saliva samples will be collected from the participants at set points during the study to look at any changes in salivary pH.

Enrollment

16 patients

Sex

All

Ages

18+ years old

Volunteers

Accepts Healthy Volunteers

Inclusion criteria

  1. Consent: Demonstrates understanding of the study and willingness to participate as evidenced by voluntary written informed consent and has received a signed and dated copy of the informed consent form.

  2. Age: Aged at least 18 years.

  3. Compliance: Understands and is willing, able and likely to comply with all study procedures and restrictions.

  4. General Health: Good general health with (in the opinion of the investigator or medically qualified designee) no clinically significant and relevant abnormalities of medical history or physical examination.

  5. Diagnosis:

    1. Study teeth must show no signs of exposed dentine at the cervical margin.
    2. In the opinion of the investigator the study teeth must have a healthy gingiva as determined during the OST examination.

Exclusion criteria

  1. Pregnancy Women who are known to be pregnant or who are intending to become pregnant over the duration of the study.

  2. Breast-feeding Women who are breast-feeding.

  3. Disease

    1. Current or recurrent disease/dental pathology that could affect the assessments.
    2. In the judgement of the investigator or medically qualified designee, any condition or medication which is causing cause Xerostomia.
    3. Diabetes Mellitus.
    4. Susceptibility to acid regurgitation.
    5. Be susceptible to high dental erosion after drinking acidic soft drinks or juices
  4. General Dental Exclusions

    1. Any orthodontic appliances, restorations, bridgework or dentures that would interfere with the study evaluations or scheduled for such treatment within the timescale of the study.
    2. Recurrent or regular aphthous ulcers.
    3. Severe gingivitis, carious lesions treated and untreated periodontal disease.
    4. Excessive signs of dental erosion or a previous history of being susceptible to high dental erosion after drinking acidic drinks
    5. Tooth bleaching within past 2 months.
    6. Suffer from dentine hypersensitivity.
  5. Allergy/Intolerance Known or suspected intolerance or hypersensitivity to the study materials (or closely related compounds) or any of their stated ingredients.

  6. Clinical Study/Experimental Medication

    1. Participation in another clinical study or receipt of an investigational drug within 30 days of the screening visit.
    2. Previous randomisation into this study.
  7. Substance abuse Recent history (within the last year) of alcohol or other substance abuse.

  8. Personnel An employee of the sponsor, member of the study site or a staff family relative. The site for this protocol is the Clinical Trials Unit in the Bristol Dental School and Hospital. Employees of the Bristol Dental School and Hospital not associated with the Clinical Trials Unit are eligible to participate.

  9. Any participant who, in the judgement of the investigator, should not participate in the study.

Trial design

Primary purpose

Treatment

Allocation

Randomized

Interventional model

Crossover Assignment

Masking

Triple Blind

16 participants in 2 patient groups, including a placebo group

RS01
Experimental group
Description:
oral care product containing containing sodium monofluorophosphate and sodium fluoride
Treatment:
Other: RS01
Water
Placebo Comparator group
Description:
Water
Treatment:
Other: Water

Trial contacts and locations

1

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2026 Veeva Systems